The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Regression of smoldering myeloma with Gaucher disease treatment
Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, discusses recent findings on patients with both smoldering myeloma and Gaucher disease. Some patients who have not been put on treatment for Gaucher disease early on in life develop smoldering myeloma due to an immunogenic response to accumulated glycolipids. Administration of Gaucher disease therapy to these patients results in both Gaucher and myeloma improving. This highlights the importance of a multidisciplinary approach to treating patients with both Gaucher disease and myeloma. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
